|
|
Dr. Steve Nissen, Chairman of Cardiovascular Medicine, discusses the results the ODYSSEY trail looking at the PCSK9 inhibitor alirocumab in patients who had a prior acute coronary syndrome and were…
|
|
|
Dr. Stephen Ellis summarizes the discussions surrounding bioabsorbable scaffolding or stents: why they were hypothesized, the results of the trials; and where we are now.
|
|
|
Dr. Steve Nissen discusses the results of three important late breaking trials looking at the impact of three drugs on cardiovascular endpoints: the CANTOS trial (Canakinumab); the REVEAL study…
|
|
|
Dr. Stephen Ellis discusses the results of recent trials at ACC related to Instantaneous Wave-Free Ration (iFR) and how the results impact practice in the cath lab.
|
|
|
Dr. Stephen Ellis discusses the results of recent bioresorbable stent trials including the ABSORB III trial and what the results mean for clinical practice.
|